Effect of arginase inhibition on ischemia-reperfusion injury in patients with coronary artery disease with and without diabetes mellitus

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kövamees, Oskar ^a   Shemyakin, Alexey ^a   Pernow, John ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; N(G) HYDROXYARGININE; SODIUM CHLORIDE; ARGINASE; ENZYME INHIBITOR; VASODILATOR AGENT;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FLOW MEDIATED DILATATION; FOREARM; HEART PROTECTION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; VASODILATATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; ARGINASE; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; RADIAL ARTERY; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 84904980514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103260     Document Type: Article

References (29)

1. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, et al. (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127: 529-555.
2. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357: 1121-1135.
3. Hausenloy DJ, Yellon DM (2013) Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123: 92-100.
4. Darra E, Rungatscher A, Carcereri de Prati A, Podesser BK, Faggian G, et al. (2010) Dual modulation of nitric oxide production in the heart during ischaemia/reperfusion injury and inflammation. Thromb Haemost 104: 200-206.
5. Cohen MV, Yang XM, Downey JM (2006) Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res 70: 231-239. (Pubitemid 44316808)
6. Jones SP, Bolli R (2006) The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40: 16-23. (Pubitemid 43012113)
7. Wang QD, Pernow J, Sjoquist PO, Ryden L (2002) Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 55: 25-37. (Pubitemid 34618530)
8. Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118: 1915-1919.
9. Durante W, Johnson FK, Johnson RA (2007) Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 34: 906-911. (Pubitemid 47083958)
10. Pernow J, Jung C (2013) Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res 98: 334-343.
11. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, et al. (2003) Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. Faseb J 17: 2328-2330. (Pubitemid 39561482)
12. Jung C, Gonon AT, Sjoquist PO, Lundberg JO, Pernow J (2010) Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res 85: 147-154.
13. Gonon AT, Jung C, Katz A, Westerblad H, Shemyakin A, et al. (2012) Local arginase inhibition during early reperfusion mediates cardioprotection via increased nitric oxide production. PLoS One 7: e42038.
14. Gronros J, Kiss A, Palmer M, Jung C, Berkowitz D, et al. (2013) Arginase inhibition improves coronary microvascular function and reduces infarct size following ischaemia-reperfusion in a rat model. Acta Physiol (Oxf) 208: 172-179.
15. Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, et al. (2012) Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation 126: 2943-2950.
16. Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458.
17. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, et al. (2005) Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: 7-17. (Pubitemid 40128972)
18. Settergren M, Bohm F, Ryden L, Pernow J (2008) Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 29: 1753-1760. (Pubitemid 352019812)
19. Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, et al. (2001) Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 103: 1624-1630. (Pubitemid 32246608)
20. Pernow J, Bohm F, Beltran E, Gonon A (2003) L-arginine protects from ischemia-reperfusion-induced endothelial dysfunction in humans in vivo. J Appl Physiol (1985) 95: 2218-2222.
21. Bohm F, Settergren M, Gonon AT, Pernow J (2005) The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. Clin Sci (Lond) 108: 357-363. (Pubitemid 40516999)
22. Lee MG, Jeong MH, Lee KH, Park KH, Sim DS, et al. (2012) Prognostic impact of diabetes mellitus and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention. J Cardiol 60: 257-263.
23. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, et al. (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34: 3035-3087.
24. Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, et al. (2012) The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 55: 600-607.
25. Gronros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, et al. (2011) Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 300: H1174-1181.
26. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, et al. (2009) Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol (1985) 107: 1249-1257.
27. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, et al. (2008) Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95-102.
28. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, et al. (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26: 1235-1241.
29. Inaba Y, Chen JA, Bergmann SR (2010) Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 26: 631-640.